Dronedarone associated with liver injury risk: FDA
Dronedarone is indicated for the treatment of abnormal heart rhythm in patients who have had an abnormal heart rhythm during the past six months. According to the FDA,
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.
Raman Extended Computational Application Platform (RECAP) brings patented technology in computational sensors, materials verification and identification software to developers, solutions providers and equipment suppliers. Centice claims Recap is